Ultrasound Liver Intraoperative Imaging With SonoVue®

Hypothesis: Use of contrast ultrasound showed interesting results, which can increase ultrasonography sensitivity performed during surgery in the evaluation of operable liver metastases.

This study is a two-stage phase II multicenter study (Simon's two-stage).

Inclusion criteria

• Patient with histological proven colorectal cancer.
• Operable liver metastases according to preoperative imagery. Operability is the possibility of treatment by resection and/or local destruction (radiofrequency, cryotherapy…).
• Patient treated or not with preoperative chemotherapy.
• With or without extra-hepatic metastases
• Age ≥ 18 years.
• Radiological assessment by CT and MRI liver and positron emission tomography scan (PETscan) within six weeks before surgery.
• Patient affiliated to the Social Security system.
• Signed informed consent.

Exclusion criteria

• Known hypersensitivity to sulfur hexafluoride or another component of SonoVue®.
• Patients with recent acute coronary syndrome or suffering from unstable ischemic heart disease, especially: evolving myocardial infarction, unstable angina during the last 7 days, recent coronary intervention or another factor suggesting clinical instability, acute heart failure, class III or IV heart failure, severe arrhythmias.
• Patients with right-to-left shunt, severe pulmonary arterial hypertension, uncontrolled systemic hypertension, as patients suffering from respiratory distress syndrome.
• Pregnant and lactating women.
• Patients with contraindication for a CT scan, a MRI or a positron emission tomography (PET) with contrast.
• Patients with indication of two step liver surgery.
• Patients already included in the study.
• Patient who couldn't be treated or followed up according to study criteria for psychological, social, family or geographical reasons. Patient deprived of liberty or under guardianship.